. 2017 Jul 13;8(33):55176–55186. doi: 10.18632/oncotarget.19220

Table 3. Decline of total symptoms scores in the group itself and between two groups.

Time	Group	N	PO-PR $\bar{X}$ ± s (95%CI)	Within-group		T-C $\bar{X}$ ± s (95%CI)	Between-group
Time	Group	N	PO-PR $\bar{X}$ ± s (95%CI)	t-test	P-value	T-C $\bar{X}$ ± s (95%CI)	F	P-value
Day 2	T	118	9.31 ± 4.41 (8.51, 10.12)	22.94	< 0.0001	−1.78 ± 0.60 (0.60, 2.96)	9.5	0.002^#
Day 2	C	118	7.53 ± 4.75 (6.67, 8.40)	17.21	< 0.0001	−1.78 ± 0.60 (0.60, 2.96)	9.5	0.002^#
Day 3	T	118	14.96 ± 5.80 (13.90, 16.02)	28.00	< 0.0001	−2.11 ± 0.82 (0.49, 3.73)	6.94	0.009^#
Day 3	C	118	12.85 ± 6.82 (11.60, 14.09)	20.47	< 0.0001	−2.11 ± 0.82 (0.49, 3.73)	6.94	0.009^#
Day 4	T	118	16.60 ± 5.51 (15.60, 17.61)	32.72	< 0.0001 −1.02 ± 0.78	(−0.53, 2.56)	1.99	0.160
Day 4	C	118	15.58 ± 6.47 (14.40, 16.76)	26.15	< 0.0001	(−0.53, 2.56)	1.99	0.160
Day 6	T	118	17.65±5.83 (16.59,18.71)	32.92	< 0.0001 −0.44 ± 0.84	(−1.21, 2.09)	0.36	0.547
Day 6	C	118	17.21±6.98 (15.94,18.48)	26.79	< 0.0001	(−1.21, 2.09)	0.36	0.547

T: treatment group (RDNI); C:controlgroup(Oseltamivir); PO−PR, post treatment score minus prior treatment score; $\bar{X}$ ± s: Mean ± SD; T−C: treatment group score minus control group score, and ^#significant difference between groups.